We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
In the latest trading session, Moderna (MRNA - Free Report) closed at $43.00, marking a +2.8% move from the previous day. The stock's change was more than the S&P 500's daily loss of 2.06%. On the other hand, the Dow registered a loss of 1.76%, and the technology-centric Nasdaq decreased by 2.39%.
Prior to today's trading, shares of the biotechnology company had gained 19.86% outpaced the Medical sector's loss of 0.88% and the S&P 500's gain of 1.63%.
The investment community will be closely monitoring the performance of Moderna in its forthcoming earnings report. On that day, Moderna is projected to report earnings of -$2.81 per share, which would represent a year-over-year decline of 12.4%. In the meantime, our current consensus estimate forecasts the revenue to be $662.39 million, indicating a 31.43% decline compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.95 per share and revenue of $1.93 billion. These totals would mark changes of +10.37% and 0%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Moderna. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 1.49% rise in the Zacks Consensus EPS estimate. At present, Moderna boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Moderna (MRNA - Free Report) closed at $43.00, marking a +2.8% move from the previous day. The stock's change was more than the S&P 500's daily loss of 2.06%. On the other hand, the Dow registered a loss of 1.76%, and the technology-centric Nasdaq decreased by 2.39%.
Prior to today's trading, shares of the biotechnology company had gained 19.86% outpaced the Medical sector's loss of 0.88% and the S&P 500's gain of 1.63%.
The investment community will be closely monitoring the performance of Moderna in its forthcoming earnings report. On that day, Moderna is projected to report earnings of -$2.81 per share, which would represent a year-over-year decline of 12.4%. In the meantime, our current consensus estimate forecasts the revenue to be $662.39 million, indicating a 31.43% decline compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.95 per share and revenue of $1.93 billion. These totals would mark changes of +10.37% and 0%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Moderna. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 1.49% rise in the Zacks Consensus EPS estimate. At present, Moderna boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.